keyword
MENU ▼
Read by QxMD icon Read
search

Lisa DeAngelis

keyword
https://www.readbyqxmd.com/read/27810565/frequency-and-predictors-of-acute-hospitalization-before-death-in-patients-with-glioblastoma
#1
Eli L Diamond, Katherine S Panageas, Alexis Dallara, Ariel Pollock, Allison J Applebaum, Alan C Carver, Elena Pentsova, Lisa M DeAngelis, Holly G Prigerson
CONTEXT: Glioblastoma (GBM) is a devastating and incurable neuro-oncologic disease, and issues related to the end of life are almost invariably a matter of "when," not a matter of "if." Optimizing symptom management and quality of life in later stages of disease is of the utmost priority. OBJECTIVES: To examine the frequency of and factors associated with late acute hospital admission before death in patients with GBM. METHODS: Case-control study comparing patients with GBM admitted to the hospital within one month of death to those without late hospital admission...
November 1, 2016: Journal of Pain and Symptom Management
https://www.readbyqxmd.com/read/27713090/a-comprehensive-assessment-of-toxicities-in-patients-with-central-nervous-system-lymphoma-undergoing-autologous-stem-cell-transplantation-using-thiotepa-busulfan-and-cyclophosphamide-conditioning
#2
Michael Scordo, Valkal Bhatt, Meier Hsu, Antonio M Omuro, Matthew J Matasar, Lisa M DeAngelis, Parastoo B Dahi, Craig H Moskowitz, Sergio A Giralt, Craig S Sauter
High-dose therapy and autologous stem cell transplantation (ASCT) with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning has emerged as an effective postinduction treatment strategy for patients with primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL), but it is associated with considerable toxicity and transplantation-related mortality (TRM) in the modern era. Forty-three adult patients with chemosensitive PCNSL or SCNSL underwent TBC-conditioned ASCT between 2006 and 2015...
October 3, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27676278/the-confused-oncologic-patient-a-rational-clinical-approach
#3
Craig Nolan, Lisa M DeAngelis
PURPOSE OF REVIEW: The purpose of this review is to provide a practical clinical approach to confusion in the patient with cancer. Confusion in the cancer population has a broader differential diagnosis than in the general medical population. The clinician must consider the usual differential diagnoses as well as causes unique to the cancer patient including direct complications from the cancer and indirect complications related to cancer treatment. RECENT FINDINGS: In the recent age of precision medicine, the oncologist now utilizes the genomic profile of both the patient and the tumor to provide advanced biologic therapies including targeted anticancer drugs, antiangiogenic agents, and immunotherapy...
December 2016: Current Opinion in Neurology
https://www.readbyqxmd.com/read/27651472/seizure-control-as-a-new-metric-in-assessing-efficacy-of-tumor-treatment-in-low-grade-glioma-trials
#4
Edward K Avila, Marc Chamberlain, David Schiff, Jaap C Reijneveld, Terri S Armstrong, Roberta Ruda, Patrick Y Wen, Michael Weller, Johan A F Koekkoek, Sandeep Mittal, Yoshiki Arakawa, Ali Choucair, Jorge Gonzalez-Martinez, David R MacDonald, Ryo Nishikawa, Aashit Shah, Charles J Vecht, Paula Warren, Martin J van den Bent, Lisa M DeAngelis
Patients with low-grade glioma frequently have brain tumor-related epilepsy, which is more common than in patients with high-grade glioma. Treatment for tumor-associated epilepsy usually comprises a combination of surgery, anti-epileptic drugs (AEDs), chemotherapy, and radiotherapy. Response to tumor-directed treatment is measured primarily by overall survival and progression-free survival. However, seizure frequency has been observed to respond to tumor-directed treatment with chemotherapy or radiotherapy...
September 20, 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27649904/marginal-zone-dural-lymphoma-the-memorial-sloan-kettering-cancer-center-and-university-of-miami-experiences
#5
Macarena I de la Fuente, Aya Haggiagi, Adrienne Moul, Robert J Young, Charif Sidani, Arnold Markoe, Francisco Vega, Lisa M DeAngelis, Izidore S Lossos
Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and nine had a biopsy. Twenty three patients could be assessed for a response to treatment after surgery. Thirteen received focal radiotherapy (RT), six whole brain RT (WBRT), three chemotherapy alone and one chemotherapy followed by WBRT. Twenty two achieved complete response (CR) and one a partial response (PR)...
September 21, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27550852/correction-regarding-data-on-blinatumomab-associated-seizures
#6
Jacqueline B Stone, Lisa M DeAngelis
No abstract text is available yet for this article.
October 2016: Nature Reviews. Clinical Oncology
https://www.readbyqxmd.com/read/27275386/anaplastic-astrocytoma-and-non-1p-19q-co-deleted-anaplastic-oligoastrocytoma-long-term-survival-employment-and-performance-status-of-survivors
#7
Elena I Pentsova, Anne S Reiner, Katherine S Panageas, Lisa M DeAngelis
BACKGROUND: Despite optimal treatment for patients with anaplastic gliomas, median survival is 2 to 5 years, but some young adults survive longer. We sought to evaluate the functional and employment status of long-term survivors (5 years or more) diagnosed with anaplastic astrocytoma or non-1p/19q co-deleted anaplastic oligoastrocytoma. METHODS: We retrospectively identified patients with a diagnosis of anaplastic glioma at Memorial Sloan Kettering Cancer Center from 1999 to 2005...
June 2016: Neuro-oncology Practice
https://www.readbyqxmd.com/read/27161972/evaluating-cancer-of-the-central-nervous-system-through-next-generation-sequencing-of-cerebrospinal-fluid
#8
Elena I Pentsova, Ronak H Shah, Jiabin Tang, Adrienne Boire, Daoqi You, Samuel Briggs, Antonio Omuro, Xuling Lin, Martin Fleisher, Christian Grommes, Katherine S Panageas, Fanli Meng, S Duygu Selcuklu, Shahiba Ogilvie, Natalie Distefano, Larisa Shagabayeva, Marc Rosenblum, Lisa M DeAngelis, Agnes Viale, Ingo K Mellinghoff, Michael F Berger
PURPOSE: Cancer spread to the central nervous system (CNS) often is diagnosed late and is unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS are largely unknown because of limited access to tumor tissue. MATERIALS AND METHODS: We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained through routine lumbar puncture in 53 patients with suspected or known CNS involvement by cancer. RESULTS: We detected high-confidence somatic alterations in 63% (20 of 32) of patients with CNS metastases of solid tumors, 50% (six of 12) of patients with primary brain tumors, and 0% (zero of nine) of patients without CNS involvement by cancer...
July 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27154916/molecular-and-clinical-effects-of-notch-inhibition-in-glioma-patients-a-phase-0-i-trial
#9
Ran Xu, Fumiko Shimizu, Koos Hovinga, Kathryn Beal, Sasan Karimi, Leif Droms, Kyung K Peck, Philip Gutin, J Bryan Iorgulescu, Thomas Kaley, Lisa DeAngelis, Elena Pentsova, Craig Nolan, Christian Grommes, Timothy Chan, Dylan Bobrow, Adilia Hormigo, Justin R Cross, Nian Wu, Naoko Takebe, Katherine Panageas, Percy Ivy, Jeffrey G Supko, Viviane Tabar, Antonio Omuro
PURPOSE: High-grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO4929097 has emerged as a potential therapeutic option based on modulation of the cancer-initiating cell (CIS) population and a presumed antiangiogenic role. EXPERIMENTAL DESIGN: In this phase 0/I trial, 21 patients with newly diagnosed glioblastoma or anaplastic astrocytoma received RO4929097 combined with temozolomide and radiotherapy. In addition to establishing the MTD, the study design enabled exploratory studies evaluating tumor and brain drug penetration and neuroimaging parameters...
October 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27106409/is-there-a-role-for-early-chemotherapy-in-the-management-of-pituitary-adenomas
#10
REVIEW
Andrew L Lin, Melissa W Sum, Lisa M DeAngelis
Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled with standard treatments that include surgical resection, radiotherapy, and agents that modulate hormonal excess. Unfortunately, a subset of patients remains uncontrolled or develops complications from these interventions. For these patients, chemotherapy is an additional treatment option that could improve outcomes. Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas...
October 2016: Neuro-oncology
https://www.readbyqxmd.com/read/27091610/comt-bdnf-and-dtnbp1-polymorphisms-and-cognitive-functions-in-patients-with-brain-tumors
#11
Denise D Correa, Jaya Satagopan, Kenneth Cheung, Arshi K Arora, Maria Kryza-Lacombe, Youming Xu, Sasan Karimi, John Lyo, Lisa M DeAngelis, Irene Orlow
BACKGROUND: Cognitive dysfunction is common among patients with brain tumors and can be associated with the disease and treatment with radiotherapy and chemotherapy. However, little is known about genetic risk factors that may moderate the vulnerability for developing cognitive dysfunction. In this study, we examined the association of single nucleotide polymorphisms (SNPs) in the catechol-O-methyl transferase (COMT), brain-derived neurotrophic factor (BDNF), and dystrobrevin-binding protein 1 (DTNBP1) genes with cognitive functions and neuroimaging outcomes in patients with brain tumors...
October 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26984218/chemotherapy-induced-peripheral-neuropathy
#12
Efstathia Tzatha, Lisa M DeAngelis
No abstract text is available yet for this article.
March 2016: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/26724834/pseudotumor-cerebri-in-acute-promyelocytic-leukemia-patients-on-intergroup-protocol-0129-clinical-description-and-recommendations-for-new-diagnostic-criteria
#13
Catherine C Coombs, Lisa M DeAngelis, James H Feusner, Jacob M Rowe, Martin S Tallman
BACKGROUND: Multiple randomized trials have demonstrated a benefit for all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL). Pseudotumor cerebri (PTC) is an infrequently reported adverse effect of ATRA. METHODS: We examined the incidence, clinical course, and outcomes of patients with APL treated on Intergroup Protocol 0129 (I0129) who developed PTC. This trial evaluated the role of ATRA alone during induction and/or as maintenance therapy...
March 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/26691210/integration-of-2-hydroxyglutarate-proton-magnetic-resonance-spectroscopy-into-clinical-practice-for-disease-monitoring-in-isocitrate-dehydrogenase-mutant-glioma
#14
Macarena I de la Fuente, Robert J Young, Jennifer Rubel, Marc Rosenblum, Jamie Tisnado, Samuel Briggs, Julio Arevalo-Perez, Justin R Cross, Carl Campos, Kimberly Straley, Dongwei Zhu, Chuanhui Dong, Alissa Thomas, Antonio A Omuro, Craig P Nolan, Elena Pentsova, Thomas J Kaley, Jung H Oh, Ralph Noeske, Elizabeth Maher, Changho Choi, Philip H Gutin, Andrei I Holodny, Katharine Yen, Lisa M DeAngelis, Ingo K Mellinghoff, Sunitha B Thakur
BACKGROUND: The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG). Prior studies showed that this metabolite can be detected in vivo using proton magnetic-resonance spectroscopy (MRS), but the sensitivity of this methodology and its clinical implications are unknown. METHODS: We developed an MR imaging protocol to integrate 2HG-MRS into routine clinical glioma imaging and examined its performance in 89 consecutive glioma patients...
February 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26308485/multicenter-phase-2-study-of-patupilone-for-recurrent-or-progressive-brain-metastases-from-non-small-cell-lung-cancer
#15
MULTICENTER STUDY
Lakshmi Nayak, Lisa M DeAngelis, H Ian Robins, Ramaswamy Govindan, Shirish Gadgeel, Karen Kelly, James R Rigas, David M Peereboom, Steven S Rosenfeld, Alona Muzikansky, Ming Zheng, Patrick Urban, Lauren E Abrey, Antonio Omuro, Patrick Y Wen
BACKGROUND: Treatment options for patients with non-small cell lung cancer (NSCLC) with brain metastases are limited. Patupilone (EPO906), a blood-brain barrier-penetrating, microtubule-targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies in patients with NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone in NSCLC brain metastases. METHODS: Adult patients with NSCLC and confirmed progressive brain metastases received patupilone intravenously at 10 mg/m(2) every 3 weeks...
December 1, 2015: Cancer
https://www.readbyqxmd.com/read/26282648/treatment-of-brain-metastases
#16
REVIEW
Xuling Lin, Lisa M DeAngelis
Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with increased surveillance and improved systemic control, the incidence is likely to grow. Despite multimodal treatment, prognosis remains poor. Current evidence supports use of whole-brain radiation therapy when patients present with multiple BMs. However, its associated cognitive impairment is a major deterrent in patients likely to live longer than 6 months. In patients with oligometastases (one to three metastases) and even some with multiple lesions less than 3 to 4 cm, especially if the primary tumor is considered radiotherapy resistant, stereotactic radiosurgery is recommended; if the BMs are greater than 4 cm, surgical resection with or without postoperative whole-brain radiation therapy should be considered...
October 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26282642/evaluation-of-the-safety-and-benefit-of-phase-i-oncology-trials-for-patients-with-primary-cns-tumors
#17
Mrinal M Gounder, Lakshmi Nayak, Solmaz Sahebjam, Alona Muzikansky, Armando J Sanchez, Serena Desideri, Xiaobu Ye, S Percy Ivy, L Burt Nabors, Michael Prados, Stuart Grossman, Lisa M DeAngelis, Patrick Y Wen
PURPOSE: Patients with high-grade gliomas (HGG) are frequently excluded from first-in-human solid tumor trials because of perceived poor prognosis, excessive toxicities, concomitant drug interactions, and poor efficacy. We conducted an analysis of outcomes from select, single-agent phase I studies in patients with HGG. We compared outcomes to pooled analysis of published studies in solid tumors with various molecular and cytotoxic drugs evaluated as single agents or as combinations. PATIENT AND METHODS: Individual records of patients with recurrent HGG enrolled onto Adult Brain Tumor Consortium trials of single-agent, cytotoxic or molecular agents from 2000 to 2008 were analyzed for baseline characteristics, toxicities, responses, and survival...
October 1, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26261221/rates-and-risks-for-late-referral-to-hospice-in-patients-with-primary-malignant-brain-tumors
#18
Eli L Diamond, David Russell, Maria Kryza-Lacombe, Kathryn H Bowles, Allison J Applebaum, Jeanne Dennis, Lisa M DeAngelis, Holly G Prigerson
BACKGROUND: Primary malignant brain tumors (PMBTs) are devastating malignancies with poor prognosis. Optimizing psychosocial and supportive care is critical, especially in the later stages of disease. METHODS: This retrospective cohort study compared early versus late hospice enrollment of PMBT patients admitted to the home hospice program of a large urban, not-for-profit home health care agency between 2009 and 2013. RESULTS: Of 160 patients with PMBT followed to death in hospice care, 32 (22...
January 2016: Neuro-oncology
https://www.readbyqxmd.com/read/26032137/posterior-reversible-encephalopathy-syndrome-in-patients-with-cancer
#19
Samuel Singer, Christian Grommes, Anne S Reiner, Marc K Rosenblum, Lisa M DeAngelis
BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) is characterized by neurologic symptoms with typical lesions on neuroimaging and may be associated with chemotherapy and immunosuppressive agents used in patients with cancer. We described the spectrum of PRES at a major cancer center. METHODS: We reviewed charts of adults with PRES between 2005 and 2011 at Memorial Sloan Kettering Cancer Center for clinical information and outcome. RESULTS: We identified 21 women (68%) and 10 men (median cohort age: 58 years)...
July 2015: Oncologist
https://www.readbyqxmd.com/read/25939273/neuro-oncology-primary-cns-lymphoma-treatment-the-devil-is-in-the-details
#20
COMMENT
Lisa M DeAngelis
No abstract text is available yet for this article.
June 2015: Nature Reviews. Neurology
keyword
keyword
71962
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"